DURHAM – Chimerix has named Allen Melemed, an MD and a former Elil Lilly executive, as its chief medical officer.
The biopharma firm focuses on conology medicines and treatments for other diseases.
“His vast experience bringing oncology therapeutics through development and approval across multiple modalities will be invaluable as we initiate our dociparstat sodium (DSTAT) Phase 3 trial in first line acute myeloid leukemia (AML), our ongoing Phase 2/3 trial to combat acute lung injury (ALI) in COVID-19 patients, and finalize our rolling New Drug Application (NDA) for brincidofovir (BCV) as a medical countermeasure for smallpox,” said Mike Sherman, Chief Executive Officer of Chimerix, in the announcement made early Monday.
Melemed previously worked at Eli Lilly for more than two decades and was actively involved in development of several oncology medicines.
Melemed “holds a B.S. in Genetics and Cell Biology from the University of Minnesota and a M.D. from the University of Minnesota School of Medicine. In addition, he completed his residency in pediatrics at the University of Wisconsin, Madison and fellowship in pediatric hematology/oncology at IU School of Medicine. He earned an M.B.A. from the University of Chicago Booth School of Business. Dr. Melemed has authored dozens of scientific and clinical publications,” the company said.
